Patents Represented by Attorney Gloria K. Szakiel
-
Patent number: 8273356Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.Type: GrantFiled: November 24, 2009Date of Patent: September 25, 2012Assignee: Pfizer Inc.Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
-
Patent number: 8241669Abstract: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal.Type: GrantFiled: January 22, 2010Date of Patent: August 14, 2012Assignee: Wyeth LLCInventors: Shobhan S. Sabnis, Jon Hayes, Jack A. Zupan
-
Patent number: 7714111Abstract: The invention relates to methods for isolating a product and/or reducing turbidity and/or impurities from a load fluid comprising the product and one or more impurities by passing the load fluid through a medium, followed by at least one wash solution comprising an arginine derivative, and collecting the product using an elution solution. The invention further relates to a product prepared using a method as described herein.Type: GrantFiled: September 7, 2007Date of Patent: May 11, 2010Assignee: Wyeth LLCInventors: Shujun Sun, Christopher Gallo
-
Patent number: 7687240Abstract: A process for producing isolated and purified respiratory syncytial virus (RSV) fusion (F) and attachment (G) glycoproteins in eukaryotic cell cultures infected with RSV cold-passaged, temperature-sensitive mutant subgroup A2 strain cpts-248/404 results in at least a 5-fold increase in F and G protein yields when compared with the parent A2 strain. Immunogenic compositions comprising the F and/or G protein(s) produced by this process can be formulated for in vivo administration to a host to confer protection against disease caused by RSV.Type: GrantFiled: March 17, 2004Date of Patent: March 30, 2010Assignee: Wyeth Holdings CorporationInventors: Firelli Alonso-Caplen, Mark Cutler, Mirelli Fino, Earl Pursell, Robert Repetto
-
Patent number: 7687471Abstract: The present invention provides a stable veterinary oral composition which comprises one or more surfactants, a water-miscible solvent, optionally an oil and an effective amount of each of a benzimidazole antihelmintic compound, such as triclabendazole and a macrocyclic lactone, such as moxidectin. Said composition is useful for treating and controlling endo- and ectoparasitic infection and infestation in a homeothermic animal.Type: GrantFiled: December 5, 2006Date of Patent: March 30, 2010Assignee: Wyeth LLCInventors: Jon C. Hayes, Debora L. Guido, Jacob A. Zupan
-
Patent number: 7674475Abstract: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal.Type: GrantFiled: December 24, 2004Date of Patent: March 9, 2010Assignee: Wyeth LLCInventors: Shobhan S. Sabnis, Jon Hayes, Jack A. Zupan
-
Patent number: 7666433Abstract: The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineered with deletions of amino acids 151-221 and 178-219. Both RSV strains replicated in the respiratory tract of BALB/c mice and elicited serum neutralization and anti-F protein IgG titers that were equivalent to cp-RSV and contributed to a 3.9 log10 reduction in RSV A2 four days after challenge. Importantly, pulmonary eosinophilia was significantly diminished in BALB/c mice primed with native G protein and challenged with either recombinant RSV strain. These findings are important for the development of immunogenic compositions against RSV.Type: GrantFiled: June 29, 2005Date of Patent: February 23, 2010Assignee: Wyeth Holdings CorporationInventors: Gerald E. Hancock, Matthew B. Elliott
-
Patent number: 7666444Abstract: There is provided an improved antiparasitic composition comprising an antiparasitically effective amount of an organic amine salt of closantel optionally a macrocyclic lactone and a non-irritating solvent system consisting essentially of an alcohol and a glycol derivative. Also provided are a method for obtaining increased levels of closantel in the blood of a homeothermic animal and a method for the enhanced protection of said animal from parasitic infection.Type: GrantFiled: January 14, 2005Date of Patent: February 23, 2010Assignee: WyethInventor: Robert Bruce Albright
-
Patent number: 7645863Abstract: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.Type: GrantFiled: January 29, 2008Date of Patent: January 12, 2010Assignee: Wyeth LLCInventors: Isidoro H. Sorokin, Paola Di Raimondo, Chin-Liang Chou
-
Patent number: 7589108Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: GrantFiled: September 29, 2005Date of Patent: September 15, 2009Assignee: WyethInventors: Ronald Charles Bernotas, Steven Edward Lenicek
-
Patent number: 7585876Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.Type: GrantFiled: November 16, 2007Date of Patent: September 8, 2009Assignee: WyethInventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
-
Patent number: 7560470Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.Type: GrantFiled: May 15, 2007Date of Patent: July 14, 2009Assignee: WyethInventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
-
Patent number: 7544701Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: GrantFiled: July 22, 2004Date of Patent: June 9, 2009Assignee: WyethInventors: Derek Cecil Cole, Ronald Charles Bernotas
-
Patent number: 7534801Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor.Type: GrantFiled: October 8, 2004Date of Patent: May 19, 2009Assignee: WyethInventor: Lynne Padilla Greenblatt
-
Patent number: 7501421Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: GrantFiled: May 31, 2007Date of Patent: March 10, 2009Assignee: WyethInventors: Kevin Liu, Albert Jean Robichaud, Hassan Mahmoud Elokdah
-
Patent number: 7498327Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.Type: GrantFiled: June 22, 2005Date of Patent: March 3, 2009Assignee: WyethInventors: Youchu Wang, Chia-Cheng Shaw, Ronald Charles Bernotas, Chung-Chiee Paul Wang, Ping Cai, Zhi Wang
-
Patent number: 7482461Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.Type: GrantFiled: April 4, 2007Date of Patent: January 27, 2009Assignee: WyethInventors: Kevin Liu, Albert Jean Robichaud, Jennifer Rebecca Lo, Hassan Mahmoud Elokdah
-
1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
Patent number: 7411064Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptorType: GrantFiled: February 15, 2006Date of Patent: August 12, 2008Assignee: WyethInventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li -
Patent number: 7348417Abstract: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.Type: GrantFiled: July 20, 2004Date of Patent: March 25, 2008Assignee: WyethInventors: Isidoro H. Sorokin, Paola Di Raimondo, Chin-Liang Chou